


in which:

- R_1 represents:


- (i) a $-CH_3$ radical,
- (ii) a radical $-CH_2-O-R_5$,
- (iii) a radical $-COR_6$,

R_5 and R_6 having the meanings given below,


- Ar represents a radical [chosen] selected from the group of radicals of formulae (a) - (e) below:




(a)




(b)



(c)



(d)



(e)

R_7 having the meaning given below

- R_2 and R_3 , which may be identical or different, independently represent a radical [chosen] selected from the group consisting of:

- (i) a hydrogen atom,
- (ii) a radical [chosen] selected from tert-butyl, 1-methylcyclohexyl and 1-adamantyl radicals,
- (iii) a radical $-OR_8$, R_8 having the meaning given below, and

(iv) a polyether radical, it being understood that at least one of the radicals R_2 or R_3 represents a radical (ii),

- R_2 and R_3 taken together can form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom,

- R_4 represents a hydrogen atom, a halogen atom, a lower alkyl radical, a radical OR_9 , a polyether radical or a radical COR_{10} ,

R_9 and R_{10} having the meanings given below,

- R_5 represents a hydrogen atom, a lower alkyl radical or a radical COR_{11} ,

R_{11} having the meaning given below,

- R_6 represents a radical [chosen] selected from the group consisting of:


(i) a hydrogen atom,

(ii) a lower alkyl radical,

(iii) a radical OR_{12} ,


R_{12} having the meaning given below, and

(iv) a radical of formula



R' and R'' having the meanings given below,

- R_7 represents a hydrogen atom, a halogen atom, a lower alkyl radical, a nitro radical, a radical OR_{13} , a polyether radical or a radical of the following formula:



R₁₃, R₁₄ and R₁₅ having the meanings given below,

- R₈ represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monohydroxyalkyl or polyhydroxyalkyl radical or a lower acyl radical,

- R₉ represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical, an optionally substituted aralkyl radical, a monohydroxyalkyl or polyhydroxyalkyl radical, a lower acyl radical, a radical $-(CH_2)_n-COOR_{16}$ or a radical $-(CH_2)_n-X$,

n, R₁₆ and X having the meanings given below,

- R₁₀ and R₁₁, which may be identical or different, represent a lower alkyl radical,

- R₁₂ represents a hydrogen atom, a lower alkyl radical, an optionally substituted aryl or aralkyl radical, a monohydroxyalkyl radical or a polyhydroxyalkyl radical,

- R' and R'', which may be identical or different, represent a hydrogen atom, a lower alkyl radical, an optionally substituted aryl radical or an amino acid residue, or alternatively R' and R'' taken together can form, with the nitrogen atom, a heterocycle,

- R₁₃ represents a hydrogen atom or a lower alkyl radical,

- R₁₄ and R₁₅, which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R₁₆ represents a hydrogen atom or a lower alkyl radical,

- n represents an integer between 1 and 12 inclusive,

- X represents a halogen atom, and the optical and geometrical isomers of the said compounds of formula (I), as well as the salts thereof.

2. (Amended) Compounds according to Claim 1, [characterized in that they] which are in the form of salts of an alkali metal or alkaline-earth metal, of zinc, of an organic amine or of an inorganic or organic acid.

3. (Amended) Compounds according to [either of Claims 1 and 2] claim 1, [characterized in that] wherein the lower alkyl radicals are [chosen] selected from the group consisting of methyl, ethyl, isopropyl, butyl and tert-butyl radicals.

4. (Amended) Compounds according to [one of the preceding claims] claim 1, [characterized in that] wherein the monohydroxyalkyl radicals correspond to radicals containing 2 or 3 carbon atoms, [in particular a 2-hydroxyethyl, 2-hydroxypropyl or 3-hydroxypropyl radical,] it being possible for the monohydroxyalkyl radical to be protected in the form of acetyl or tertbutyldimethylsilyl.

5. (Amended) Compounds according to [one of the preceding claims] claim 1, [characterized in that] wherein the polyhydroxyalkyl radicals are [chosen] selected from the group consisting of 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl and 2,3,4,5-

tetrahydroxypentyl radicals or a pentaerythritol residue, it being possible for the hydroxyl groups to be protected in the form of acetyls or tert-butyldimethylsilyls.

6. (Amended) Compounds according to [one of the preceding claims] claim 1, [characterized in that] wherein the aryl radicals correspond to a phenyl radical, optionally substituted with at least one halogen, one hydroxyl or one nitro function.

7. (Amended) Compounds according to [one of the preceding claims] claim 1, [characterized in that] wherein the aralkyl radicals are [chosen] selected from the group consisting of benzyl and phenethyl radicals optionally substituted with at least one halogen, one hydroxyl or one nitro function.

8. (Amended) Compounds according to [one of the preceding claims] claim 1, [characterized in that] wherein the lower acyl radicals are [chosen] selected from the group consisting of an acetyl radical [or] and a propionyl radical.

9. (Amended) Compounds according to [any one of the preceding claims] claim 1, [characterized in that] wherein the polyether radicals are [chosen] selected from the group consisting of methoxymethyl ether, methoxyethoxymethyl ether and methylthiomethyl ether radicals.

10. (Amended) Compounds according to [any one of the preceding claims] claim 1, [characterized in that] wherein the amino acid residues are [chosen] selected from the group consisting of residues derived from lysine, glycine [or from] and aspartic acid.

11. (Amended) Compounds according to [any one of the preceding claims] claim 1, [characterized in that] wherein the heterocyclic radicals are [chosen] selected from the group consisting of piperidino, morpholino, pyrrolidino and piperazino radicals, optionally substituted in position 4 with a C₁-C₆ alkyl radical or with a mono- or polyhydroxyalkyl radical.

12. (Amended) Compounds according to Claim 1, [characterized in that they] which are taken, alone or as mixtures, from the group consisting of:
ethyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, ethyl 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, ethyl 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(5,5,8,8-tetramethyl-3-propoxy-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 3-(4-tert-butylphenylselanyl)benzoic acid, 6-(4-tert-butylphenylselanyl)nicotinic acid, 4-(4-tert-butylphenylselanyl)benzoic acid, 4-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid, 3-(4,4-dimethylthiochroman-8-ylselanyl)benzoic acid, 6-(4,4-dimethylthiochroman-8-

ylselanyl)nicotinic acid, 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 6-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 4-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-2-methylphenylselanyl]benzoic acid, 3-[5-adamantan-1-yl-4-(2-methoxyethoxymethoxy)-2-methylphenylselanyl]benzoic acid, 6-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 4-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-3-methoxybenzoic acid, 3-(4-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-4-methoxybenzoic acid, 6-(4-methoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 2-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 3-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, 6-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)nicotinic acid, 2-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)nicotinic acid, 4-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)benzoic acid, 3-(3,5-di-tert-butyl-2-methoxymethoxyphenylselanyl)benzoic acid, 6-[4-adamantan-1-yl-3-benzyloxyphenylselanyl)nicotinic acid, 6-(3,5-di-tert-butyl-2-

benzyloxyphenylselanyl)nicotinic acid, 3-methoxy-4-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 4-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 6-(4-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 3-methoxy-4-(3-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)benzoic acid, 6-(3-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 4-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)-3-methoxybenzoic acid, 6-(3-hexyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylselanyl)nicotinic acid, 4-(5-adamantan-1-yl-4-benzyloxy-2-methylphenylselanyl)-benzoic acid, 6-[3-(5-hydroxypentyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, ethyl 4-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, ethyl 4-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoate, 4-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)benzoic acid, ethyl 6-(3-methoxyethoxymethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, ethyl 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinate, 6-(3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinic acid, ethyl 6-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate, 6-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 4-[3-(3-ethoxycarbonylpropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate, 4-[3-(3-carboxypropoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-

2-naphthylselanyl]benzoic acid, ethyl 4-[3-(7-methoxycarbonylheptyloxy)-5,5,8,8-tetra-
methyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate, 4-[3-(7-carboxyheptyloxy)-5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid, ethyl 6-[3-(7-
methoxycarbonylheptyloxy)-5,5,8,8-tetra-methyl-5,6,7,8-tetrahydro-2-
naphthylselanyl]nicotinate, 6-[3-(7-carboxyheptyloxy)-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 6-[3-(2-acetoxyethoxy)-5,5,8,8-
tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinate, 6-[3-(2-hydroxyethoxy)-
5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]nicotinic acid, ethyl 4-[3-(2-
acetoxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoate, 4-[3-(2-
hydroxyethoxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthylselanyl]benzoic acid, 6-
(3-adamantan-1-yl-4-methoxyphenylselanyl)nicotinic acid, [6-(3,5,5,8,8-pentamethyl-
5,6,7,8-tetrahydro-2-naphthylselanyl)-3-pyridyl]methanol, N-ethyl-6-(3,5,5,8,8-
pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)nicotinamide, morpholin-4-yl-[6-
(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthylselanyl)-3-pyridyl]methanone, N-(4-
hydroxyphenyl)-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-
naphthylselanyl)nicotinamide, 6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-
naphthylselanyl)pyridine-3-carbaldehyde.

13. (Amended) Compounds according to Claim 1, [characterized in that they]
which have at least one, [and preferably all,] of the following characteristics:

- R₁ represents a radical COR₆
- Ar represents a radical of formula (a) or (b)

2ul
B1
R₂ or R₃ represents an adamantyl radical or R₂ and R₃ taken together form, with the adjacent aromatic ring, a 5- or 6-membered saturated ring optionally substituted with methyl groups and/or optionally interrupted with an oxygen or sulphur atom.

15. (Amended) [Compounds according to Claim 14, for use as medicinal products intended] A method for treating dermatological complaints associated with a keratinization disorder which has a bearing on differentiation and on proliferation[, in particular for treating common acne, comedones, polymorphonuclear leukocytes, rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acnes such as solar, medication-related or occupational acne]; for treating other types of keratinization disorder[, in particular ichthyosis, ichthyosiform states, Darier's disease, palmoplantar keratoderma, leucoplasias and leucoplasiform states, and cutaneous or mucous (buccal) lichen]; for treating other dermatological complaints associated with a keratinization disorder with an inflammatory and/or immunoallergic component [and, in particular, all forms of psoriasis, whether it is cutaneous, mucous or unguial psoriasis and even psoriatic rheumatism, or alternatively cutaneous atopy, such as eczema or respiratory atopy or alternatively gingival hypertrophy]; [the compounds can also be used in certain] for treating inflammatory complaints which have no keratinization disorder; for treating all dermal or epidermal proliferations, whether benign or malignant and whether they are of viral origin or otherwise[, such as common warts, flat warts and verruciform epidermodysplasia, oral or florid papillomatoses and proliferations which may be induced by ultraviolet radiation, in particular in the case of basocellular and spinocellular epithelioma]; for treating other

dermatological disorders such as bullosis and collagen diseases; for treating certain ophthalmological disorders[, in particular corneopathies]; for repairing or combating ageing of the skin, whether this is lightinduced or chronological ageing, or for reducing actinic keratoses and pigmentations, or any pathologies associated with chronological or actinic ageing; for preventing or curing the stigmata of epidermal and/or dermal atrophy induced by local or systemic corticosteroids, or any other form of cutaneous atrophy; for preventing or treating cicatrization disorders or for preventing or repairing stretchmarks, or [alternatively] for promoting cicatrization; for combating disorders of sebaceous functioning [such as the hyperseborrhoea of acne or simple seborrhoea]; [in the treatment or prevention of] for treating or preventing cancerous or precancerous states[, more particularly promyelocyte leukaemias]; [in] for the treatment of inflammatory complaints [such as arthritis]; [in] for the treatment of any general or skin complaint of viral origin; [in] for the prevention or treatment of alopecia; [in] for the treatment of dermatological complaints having an immunological component; [in] for the treatment of complaints of the cardiovascular system [such as arteriosclerosis, hypertension, non-insulin-dependent diabetes and obesity]; [in] for the treatment of skin disorders due to an exposure to U.V. radiation comprising administering to a subject an effective amount of the compound according to claim 1 to a subject.

16. (Amended) Pharmaceutical composition[, characterized in that it comprises] comprising, in a pharmaceutically acceptable support, at least one of the compounds as defined in [any one of Claims 1 to 13] claim 1.

17. (Amended) Composition according to Claim 16, [characterized in that] wherein the concentration of compound(s) according to [one of Claims 1 to 13] claim 1 is between 0.001 % and 5 % by weight relative to the composition as a whole.

A2
09/19/19 03:30:11
17. (Amended) Cosmetic composition[, characterized in that it comprises] comprising, in a cosmetically acceptable support, at least one of the compounds as defined in [any one of Claims 1 to 13] claim 1.

19. (Amended) Composition according to Claim 18, [characterized in that] wherein the concentration of compounds [according to one of Claims 1 to 13] is between 0.001 % and 3 % by weight relative to the composition as a whole.

20. (Amended) [Use of a cosmetic composition as defined in either of Claims 18 and 19,] A method for body or hair hygiene comprising administering an effective amount of the cosmetic composition according to claim 18 to a subject.

REMARKS

Entry of the foregoing amendment(s) is respectfully requested.

The claims have been amended to eliminate multiple dependency and to place them in better condition for U.S. patent practice.